10-K: Achieve Life Sciences Faces Delays, Going Concern Doubt

Achieve Life Sciences' 2025 annual report highlights significant operating losses, ongoing financing needs, and potential FDA approval delays for cytisinicline, despite positive clinical trial results and breakthrough therapy designation.

Summary

• Achieve Life Sciences is a late-stage clinical specialty pharmaceutical company focused on developing and commercializing cytisinicline for nicotine dependence, including smoking and e-cigarette cessation.
• The FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette cessation in July 2024 and awarded a Commissioners National Priority Voucher (CNPV) in October 2025, which expedites review.
• The FDA accepted the New Drug Application (NDA) for cytisinicline for smoking cessation in September 2025, with a Prescription Drug User Fee Act (PDUFA) targeted action date of June 20, 2026.
• There is a potential for delay in FDA approval beyond June 20, 2026, due to two observations related to solid oral dose manufacturing made during a non-Achieve related FDA cGMP inspection of a third-party manufacturer named in the NDA.
• The company has partnered with Adare Pharma Solutions, a U.S.-based manufacturer, for commercial supply, with an anticipated commercial launch in the first-half 2027.
• Achieve Life Sciences reported a net loss of $54.6 million for the year ended December 31, 2025, increasing from $39.8 million in 2024, and an accumulated deficit of $260.2 million.
• As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $36.4 million, with net cash used in operating activities of $49.5 million for the year.
• Substantial doubt exists regarding the company's ability to continue as a going concern, as current resources are insufficient to fund planned operations for the next 12 months.
• The company has incurred substantial debt, with a principal amount of $15.0 million under a convertible term loan as of December 31, 2025, subject to floating interest rates.
• Research and development expenses increased slightly to $23.0 million in 2025, while general and administrative expenses significantly rose to $31.9 million, primarily due to $12.3 million in commercial launch preparation costs.
• The company raised approximately $41.2 million net from a June 2025 public offering and an additional $4.0 million net from an overallotment option exercise, and drew down $5.0 million from its convertible term loan in October 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for Achieve Life Sciences, with substantial doubt about its going concern status and potential FDA approval delays, despite promising clinical trial results for cytisinicline. The company's heavy reliance on external financing and lack of product revenue create significant financial vulnerability.

Positives

• FDA granted Breakthrough Therapy designation for cytisinicline for nicotine e-cigarette, or vaping, cessation in July 2024, which expedites development and review.
• FDA awarded cytisinicline for nicotine e-cigarette cessation the Commissioners National Priority Voucher (CNPV) in October 2025, providing enhanced communication with review staff and a decision within one to two months following complete application filing.
• FDA accepted the New Drug Application (NDA) for cytisinicline as a treatment for smoking cessation in September 2025, assigning a PDUFA targeted action date of June 20, 2026.
• Cytisinicline demonstrated significantly better quit rates than placebo in Phase 3 ORCA-2 and ORCA-3 trials for smoking cessation, and a statistically significant vaping cessation benefit in Phase 2 ORCA-V1.
• The product candidate was well-tolerated across multiple clinical trials (ORCA-1, ORCA-V1, ORCA-2, ORCA-3), with no treatment-related serious adverse events reported.
• Completed the ORCA-OL open-label study, meeting FDA requirements for six months and one year of cumulative safety exposure data for NDA submission.
• Partnership with U.S.-based Adare Pharma Solutions for manufacturing provides supply chain redundancy, U.S.-based contingency capacity, and is expected to decrease risks and costs.
• The company is actively building an intellectual property portfolio with over 20 issued patents and 50 pending applications, with expiration dates ranging from 2037 to 2042.
• Management plans to utilize a well-established marketing technology infrastructure and embed Artificial Intelligence (AI) tools to enhance targeting, decision-making, and performance metrics for commercial launch.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and dependence on additional financing.
• Reported a significant net loss of $54.6 million for 2025 and an accumulated deficit of $260.2 million as of December 31, 2025.
• Current resources are insufficient to fund planned operations for the next 12 months, necessitating substantial additional capital raises.
• Potential for a delay in FDA approval beyond the PDUFA target date of June 20, 2026, due to two cGMP inspection observations at a third-party manufacturer named in the NDA.
• The company has incurred substantial debt, with $15.0 million in principal outstanding as of December 31, 2025, subject to floating interest rates, increasing financial risk.
• A dispute with Sopharma has arisen regarding the company's engagement of third-party manufacturers, which Sopharma alleges is a breach of their supply agreement.
• No products are approved for commercialization, and the company has not generated any revenue from product sales to date.
• Increased general and administrative expenses in 2025, primarily driven by $12.3 million in commercial launch preparation costs, without corresponding product revenue.
• Cytisinicline is a naturally occurring alkaloid, which limits composition of matter patentability and could allow third parties to manufacture and sell it without royalties.
• The company is required to keep substantially all of its cash and investments with Silicon Valley Bank (SVB), a single financial institution, posing a concentration risk, especially after SVB's closure in March 2023.

Risks

• Substantial doubt exists as to the company's ability to continue as a going concern, dependent on raising additional capital.
• The company has incurred substantial debt, which could impair its flexibility and access to capital and adversely affect its financial position.
• Cytisinicline is currently the sole product candidate, and there is no guarantee of successful FDA or other regulatory approval.
• Development and commercialization are dependent on securing sufficient quantities of cytisinicline from limited plant sources outside the United States.
• Reliance on third parties for manufacturing exposes the company to risks of delays, quality issues, or failure to obtain regulatory approval (e.g., Sopharma dispute, cGMP observations).
• The FDA may not grant marketing approval of cytisinicline without additional clinical or nonclinical studies, or at all.
• Cytisinicline may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial viability, or result in negative consequences post-marketing.
• It is difficult to evaluate the current business, predict prospects, and forecast financial performance and growth due to a limited operating history and no product revenue.
• The company faces substantial competition from major pharmaceutical companies and generic products, which may develop or commercialize products faster or more successfully.
• Inability to attract, retain, and motivate qualified personnel could impede research, development, and commercialization objectives.
• Difficulties in managing organizational expansion for commercialization could disrupt operations and increase expenses.
• Investing in and being unsuccessful in developing additional indications for cytisinicline (e.g., e-cigarette cessation) could adversely affect the business.
• Internal computer systems, or those of third-party collaborators, may fail or suffer security breaches and cyber-attacks, disrupting development programs.
• Inability to establish distribution, marketing, and sales capabilities could hinder commercialization efforts.
• Failure to obtain or maintain adequate reimbursement or insurance coverage for products could limit marketability and revenue generation.
• Sopharma may breach its supply agreement and sell cytisinicline into the company's territories, negatively affecting commercialization.
• The illegal distribution and sale of counterfeit versions of cytisinicline or unapproved products could harm financial performance and reputation.
• Inability to establish or maintain third-party relationships necessary for development or commercialization.
• Inability to realize the potential benefits of any collaborations.
• Exposure to U.S. and foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws.
• Inability to maintain effective proprietary rights for product candidates, as cytisinicline is naturally occurring and not patentable as a compound.
• Third-party claims of intellectual property infringement could prevent or delay development and commercialization efforts.
• Changes in patent law could diminish the value of patents.
• Risk of securities class action litigation.
• Costs and demands upon management due to compliance with laws and regulations affecting public companies.
• Shareholder activism could disrupt the business.
• Anti-takeover provisions under Delaware law could make an acquisition more difficult.
• Bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Failure to maintain effective internal control over financial reporting could harm reputation, results of operations, and financial condition.
• Pre-merger net operating loss carryforwards and certain other tax attributes are subject to limitations under Section 382 of the U.S. Internal Revenue Code.
• U.S. federal tax reform and changes in other tax laws could increase the tax burden.
• Business may be negatively affected by weather conditions, natural disasters, and the availability of natural resources (plant sources for cytisinicline), as well as by climate change.
• Disruptions at the FDA, including government shutdowns or changes in policy, could slow review and approval processes.

Future Outlook

The company anticipates continued significant expenses and increasing operating losses for the foreseeable future as it progresses towards the anticipated commercial launch of cytisinicline in the first-half 2027. It plans to invest in the research and development of new indications, specifically for e-cigarette cessation, and will require substantial additional capital through various financing transactions. The strategy for the U.S. market involves independent commercialization with a focus on targeted audiences, leveraging marketing technology and AI tools, while seeking commercial partnerships for ex-U.S. territories.

Management Comments

• Our primary focus is to address this global epidemic [nicotine dependence].
• We believe cytisinicline is differentiated from existing smoking cessation treatments given its combination of efficacy, well-tolerated safety profile, and dosing flexibility with a 6 or 12-week regimen, as demonstrated in clinical trials.
• We believe that cytisinicline, if approved, could be the first prescription drug indicated for vape and e-cigarette users who are ready to quit their nicotine dependence.
• We believe we will be able to commercialize independently in the U.S. market by focusing our marketing and sales efforts on highly targeted prescriber and patient audiences.
• Launch planning and readiness activities are underway, leveraging our integrated agency partnership with Omnicom, with teams established for key functional areas including market access, medical education, prescriber and patient marketing, and digital infrastructure.
• Management is also responsible for hiring appropriate personnel, integrating cybersecurity considerations into our overall risk management strategy, and for communicating key priorities to employees, as well as for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.

Industry Context

StockSavvy.ai notes that the global smoking cessation market is projected to reach $5.6 billion by 2030, indicating a significant opportunity for new therapies. The company's focus on both smoking and e-cigarette cessation positions it to address a growing public health crisis, especially given the lack of FDA-approved therapies specifically for e-cigarette cessation. The re-launch of Pfizer's Chantix (varenicline) as a cash-pay product in February 2026, after its recall due to impurities, suggests a potential gap in the market for a well-tolerated prescription alternative, which cytisinicline aims to fill. The company's strategy to establish U.S. manufacturing with Adare Pharma Solutions aligns with broader industry trends towards supply chain resilience and reducing reliance on international importation, especially in light of potential tariffs and geopolitical uncertainties.

Comparison to Industry Standards

• Cytisinicline's efficacy in Phase 3 trials (ORCA-2: 32.6% abstinence at weeks 9-12 for 12-week treatment vs. 7.0% for placebo; ORCA-3: 30.3% abstinence at weeks 9-12 for 12-week treatment vs. 9.4% for placebo) suggests competitive efficacy compared to historical data for existing treatments.
• Varenicline (Chantix), prior to its recall, demonstrated continuous abstinence rates of around 33% at 6 months in some studies, while bupropion (Zyban) showed rates around 19%. Cytisinicline's 21.1% continuous abstinence rate from week 9 to 24 for the 12-week arm in ORCA-2 and 20.5% in ORCA-3 indicates competitive long-term efficacy.
• The well-tolerated safety profile of cytisinicline, with no treatment-related serious adverse events reported across multiple trials, differentiates it from varenicline and bupropion, which are associated with significant side effects including neuropsychiatric adverse events.
• The FDA's Breakthrough Therapy designation for e-cigarette cessation highlights cytisinicline's potential to offer substantial improvement over available therapies, as there are currently no FDA-approved therapies specifically for this indication, positioning Achieve Life Sciences uniquely against competitors who primarily focus on traditional smoking cessation.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceedings whose adverse outcome would have a material adverse effect on its operations or financial position.
• Sopharma has alleged that the company's engagement of third-party manufacturers constitutes a breach of their supply agreement, which the company has disputed and is seeking to resolve. This dispute could potentially lead to future litigation.

Related Party Transactions

• Entered into three development agreements with Adare Pharma Solutions between September 25, 2025, and December 22, 2025, for analytical and drug product development of cytisinicline. Thomas Sellig, a member of the company's Board of Directors and Chair of the Compensation Committee, is the Chief Executive Officer of Adare. The company expects to incur approximately $3.2 million in expenses over the term of these agreements, with $34,000 incurred in 2025 and a $0.2 million prepayment recorded.
• Entered into a consulting agreement with Kristen Slaoui on November 10, 2025, for strategic business development and transaction advisory support services. Dr. Slaoui is a member of the company's Board of Directors. The company incurred consulting fees of $13,750 for 2025, with $8,250 recorded in accounts payable and $5,500 in accrued liabilities as of December 31, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from past and future equity financings, and potential decline in stock price due to substantial doubt about the company's going concern status and regulatory delays.
• Future customers (patients) could benefit from a new, well-tolerated prescription treatment for smoking and e-cigarette cessation if cytisinicline receives regulatory approval.
• Employees' job security and potential for equity-based compensation are subject to the company's ability to secure additional financing and achieve commercial success.
• Creditors and suppliers face risk due to the company's recurring losses and dependence on external capital, with the Sopharma dispute potentially impacting a key supply relationship.
• Regulatory authorities are actively engaged in the review and approval process for cytisinicline, and their decisions will significantly impact the company's future.

Next Steps

• Address and resolve the two FDA cGMP inspection observations at the third-party manufacturer to mitigate potential approval delays.
• Continue the technology transfer process with Adare Pharma Solutions to establish U.S.-based manufacturing capacity for cytisinicline.
• Prepare for the anticipated commercial launch of cytisinicline in the first-half 2027, including building out commercial infrastructure and leveraging AI tools for marketing.
• Raise substantial additional capital through various financing mechanisms to fund ongoing operations, clinical development, and commercialization activities.
• Resolve the ongoing dispute with Sopharma regarding the engagement of third-party manufacturers.
• Initiate and complete the proposed single Phase 3 study for vaping cessation, targeting enrollment and study evaluations approximately 12 months after study initiation.
• Continue to protect and expand the intellectual property portfolio around cytisinicline and its derivatives.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, evidenced by recurring significant losses and insufficient current resources to fund operations for the next 12 months. While cytisinicline shows promise in clinical trials and has received favorable FDA designations, the potential for regulatory approval delays due to manufacturing issues and the heavy reliance on future capital raises introduce considerable uncertainty and risk for investors. The current financial position and operational challenges suggest a high probability of further dilution or financial distress, making it a high-risk investment.

Keywords

Achieve Life Sciences, Cytisinicline, Nicotine Dependence, Smoking Cessation, E-cigarette Cessation, Vaping Cessation, FDA Approval, Breakthrough Therapy, PDUFA, Clinical Trials, Pharmaceutical, Biotechnology, SEC Filing, 10-K, Financial Performance, Going Concern, Debt Financing, Manufacturing, Intellectual Property, Corporate Governance, Risk Management, Adare Pharma Solutions, Sopharma